Literature DB >> 7910526

Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487.

J M Wierda1, A M Beaufort, U W Kleef, N J Smeulers, S Agoston.   

Abstract

Three muscle relaxants, Org 9453, Org 9489 and Org 9487, short-acting in animals, were investigated to establish their profiles in humans. Potency, time course of action, and pharmacokinetic behaviour were studied in 90 healthy patients during fentanyl/halothane/N2O anaesthesia. Neuromuscular function was monitored mechanomyographically. Plasma and urine concentrations (three patients per compound) were measured by HPLC, and these data were analyzed by iterative linear least square regression analysis. The ED90 values for Org 9453, Org 9489 and Org 9487 were 1.4, 0.45 and 1.15 mg.kg-1 respectively. The onset times of Org 9453 (1.5 mg.kg-1, 1.1 X ED90), Org 9489 (0.9 mg.kg-1, 2 X ED90) and Org 9487 (1.5 mg.kg-1, 1.3 X ED90) were 1.2, 1.6 and 1.5 min, and the durations until 25% twitch recovery were 8.6, 22.0 and 8.9 min, respectively. Clearances of these doses were 6.9, 5.8, and 11.1 ml.kg-1.min-1, and mean residence times 26, 79, and 41 min, respectively. Mean renal excretion (parent compound and metabolites) within 24 hr amounted to 5, 11.3 and 12.2% respectively. No side effects other than a moderate short-lasting decrease of blood pressure and a concomittant increase in heart rate were noted. It is concluded that Org 9453 and Org 9487 are short-acting muscle relaxants in humans.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7910526     DOI: 10.1007/BF03009833

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  19 in total

1.  The neuromuscular blocking effect of Org 9426. A new intermediately-acting steroidal non-depolarising muscle relaxant in man.

Authors:  L H Booij; H T Knape
Journal:  Anaesthesia       Date:  1991-05       Impact factor: 6.955

Review 2.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

3.  Dose-response relation, neuromuscular blocking action, intubation conditions, and cardiovascular effects of Org 9273, a new neuromuscular blocking agent.

Authors:  L van den Broek; L M Lambalk; F J Richardson; J M Wierda
Journal:  Anesth Analg       Date:  1991-06       Impact factor: 5.108

4.  The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl.

Authors:  J M Wierda; U W Kleef; L M Lambalk; W D Kloppenburg; S Agoston
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

5.  A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs.

Authors:  F Donati; C Meistelman
Journal:  J Pharmacokinet Biopharm       Date:  1991-10

6.  The Relaxometer: a complete and comprehensive computer-controlled neuromuscular transmission measurement system developed for clinical research on muscle relaxants.

Authors:  C J Rowaan; R H Vandenbrom; J M Wierda
Journal:  J Clin Monit       Date:  1993-01

7.  Pancuronium, gallamine, and d-tubocurarine compared: is speed of onset inversely related to drug potency?

Authors:  A F Kopman
Journal:  Anesthesiology       Date:  1989-06       Impact factor: 7.892

8.  Clinical observations on the neuromuscular blocking action of Org 9426, a new steroidal non-depolarizing agent.

Authors:  J M Wierda; A P de Wit; K Kuizenga; S Agoston
Journal:  Br J Anaesth       Date:  1990-04       Impact factor: 9.166

9.  [Modification of organ perfusion by calcium blocker and converting enzyme inhibitor in the conscious rat with heart failure].

Authors:  H Drexler; A G Truog; H Just; R Zelis
Journal:  Klin Wochenschr       Date:  1985-03-15

10.  Effects of the new calcium antagonist PN 200-110 on the myocardium and the regional peripheral circulation in anesthetized cats and dogs.

Authors:  R P Hof; A Hof; G Scholtysik; K Menninger
Journal:  J Cardiovasc Pharmacol       Date:  1984 May-Jun       Impact factor: 3.105

View more
  8 in total

Review 1.  Clinical pharmacokinetics of the newer neuromuscular blocking drugs.

Authors:  D P Atherton; J M Hunter
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 2.  Rapacuronium bromide: a review of its use in anaesthetic practice.

Authors:  S V Onrust; R H Foster
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

3.  The role of the amino acid residue at alpha1:189 in the binding of neuromuscular blocking agents to mouse and human muscle nicotinic acetylcholine receptors.

Authors:  P G Purohit; R J Tate; E Pow; D Hill; J G Connolly
Journal:  Br J Pharmacol       Date:  2007-02-12       Impact factor: 8.739

Review 4.  Newer neuromuscular blocking agents: how do they compare with established agents?

Authors:  H J Sparr; T M Beaufort; T Fuchs-Buder
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Neuromuscular blocking profile of the vecuronium analogue, Org-9487, in the rat isolated hemidiaphragm preparation.

Authors:  C Prior; L Tian; A I el Mallah; L Young; J M Ward
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

Review 6.  Pharmacokinetics and pharmacodynamics of rapacuronium bromide.

Authors:  William J Wight; Peter M C Wright
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  Pharmacokinetic analysis of rapacuronium and its metabolite during liver transplantation: an assessment of its potential as a pharmacodynamic probe.

Authors:  Robert E Black; Ralph Gertler; Peter M C Wright; Mario T Cancemi; H A Tillmann Hein; Michael A E Ramsay
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-07

Review 8.  Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.